Literature DB >> 24812650

A current review of cytochrome P450 interactions of psychotropic drugs.

Subramoniam Madhusoodanan1, Umamaheswararao Velama, Jeniel Parmar, Diana Goia, Ronald Brenner.   

Abstract

BACKGROUND: The number of psychotropic drugs has expanded tremendously over the past few decades with a proportional increase in drug-drug interactions. The majority of psychotropic agents are biotransformed by hepatic enzymes, which can lead to significant drug-drug interactions. Most drug-drug interactions of psychotropics occur at metabolic level involving the hepatic cytochrome P450 enzyme system.
METHODS: We searched the National Library of Medicine, PsycINFO, and Cochrane reviews from 1981 to 2012 for original studies including clinical trials, double-blind, placebo-controlled studies, and randomized controlled trials. In addition, case reports, books, review articles, and hand-selected journals were utilized to supplement this review.
RESULTS: Based on the clinical intensity of outcome, cytochrome interactions can be classified as severe, moderate, and mild. Severe interactions include effects that might be acutely life threatening. They are mainly inhibitory interactions with cardiovascular drugs. Moderate interactions include efficacy issues. Mild interactions include nonserious side effects, such as somnolence.
CONCLUSIONS: Psychotropic drugs may interact with other prescribed medications used to treat concomitant medical illnesses. A thorough understanding of the most prescribed medications and patient education will help reduce the likelihood of potentially fatal drug-drug interactions.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24812650

Source DB:  PubMed          Journal:  Ann Clin Psychiatry        ISSN: 1040-1237            Impact factor:   1.567


  4 in total

Review 1.  Guidance for appropriate use of psychotropic drugs in older people.

Authors:  Andreas Capiau; Katrien Foubert; Annemie Somers; Mirko Petrovic
Journal:  Eur Geriatr Med       Date:  2021-01-08       Impact factor: 1.710

2.  Multimorbidity, polypharmacy and primary prevention in community-dwelling adults in Quebec: a cross-sectional study.

Authors:  Tu N Nguyen; Patrice Ngangue; Jeannie Haggerty; Tarek Bouhali; Martin Fortin
Journal:  Fam Pract       Date:  2019-11-18       Impact factor: 2.267

3.  Reversible Valproate Induced Pisa Syndrome and Parkinsonism in a Neuro-Oncology Patient with Depression and Epilepsy.

Authors:  Andrea Botturi; Antonio Silvani; Gabriella Pravettoni; Riccardo Augusto Paoli; Claudio Lucchiari
Journal:  Case Rep Neurol       Date:  2016-06-06

4.  Mitigating the Risk of Adverse Effects Related to Augmentation Therapy for Resistant Major Depressive Disorder: A Case Report.

Authors:  Collin J Amundson; Robert Knight; Georgina M Ybarra; Jacques Turgeon; Jennifer M Bingham
Journal:  Medicina (Kaunas)       Date:  2022-03-17       Impact factor: 2.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.